Trending...
- New Report Reveals Surprising Trends in Ohio Airport Accidents
- Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
- Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
WEST CHESTER, Pa.--(BUSINESS WIRE)--Beth Altman, former managing partner at accounting firm KPMG LLP San Diego, has joined Papyrus Therapeutics Inc. as an independent director of the Company's Board of Directors and as Chair of the Audit Committee.
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
- Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
- Best Companies Group Free Launches Best Places to Work in Michigan Program
- Billy Bob Thornton & The Boxmasters Coming to The Eichelberger Performing Arts Center This August
- EFA Announces 2026 Editorial Rate Chart
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- Why We're Holding the Line on Pricing
- Moravian Academy Announces New Full-Tuition Impact Scholarship for Upper School Students
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
- National Focus Turns to Global Conflict, Families of Veterans Lost to Suicide Call for Recognition
- New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
- Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
- Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
- ATTAIN Profiles the Invisible Billionaire Who Started With $75 and Died the Richest Man in A
- Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
- NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
- QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
- Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
- Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
- New Book Synthesizes Six Peer-Reviewed Research Programs Into Unified Framework for Consciousness
- The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
- The State of Law Firm Marketing: Top Companies, Awards, and Resources
- USA Best Book Awards Finalist What Love Leaves Behind Releases March 24
- Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago